Comments to FDA: Transdermal and Topical Delivery Systems

Share page:

Comments | Feb 19, 2020

Docket Number:

Enclosed herein are comments on “Transdermal and Topical Delivery Systems - Product Development and Quality Considerations”. CHPA and our member companies marketing external analgesic ingredients have an interest, experience, and expertise in this area and appreciate this opportunity to comment.

Related Posts